Dutpase Inhibitors
    1.
    发明申请
    Dutpase Inhibitors 失效
    Dutpase抑制剂

    公开(公告)号:US20080312183A1

    公开(公告)日:2008-12-18

    申请号:US10585283

    申请日:2005-01-06

    摘要: Deoxyuridine derivatives of the formula (I) where R1 is H or various substituents; D is —NHCO—, —CONH—, -0-, —C(═O)—, —CH═CH, —C≡C—, —NR5—; R4 is hydrogen or various substituents; R5 is H, C1-C4 alkyl, C1-C4 alkanoyl; E is Si or C; R6, R7 and R8 are independently selected from C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl or a stable monocyclic, bicyclic or tricyclic ring system; G is —O—, —S—, —CHR10—, —C(═O)—; J is —CH2—, or when G is CHR10 may also be —O— or —NH—; R10 is H, F, —CH3, —CH2NH2, —CH2OH; —OHR11 is H, F, —CH3, —CH2NH2, —CH2OH, —CH(OH)CH3, CH(NH3)CH3; or R10 and R11 together define an olefinic bond, or together form a —CH2-group, thereby defining a cis or trans cyclopropyl group; have utility in the prophylaxis or treatment of protozoal diseases such as malaria.

    摘要翻译: 式(I)的脱氧尿苷衍生物,其中R 1为H或各种取代基; D是-NHCO-,-CONH - , - O - , - C(-O) - , - CH-CH,-C≡C-,-NR5-; R4是氢或各种取代基; R5是H,C1-C4烷基,C1-C4烷酰基; E为Si或C; R 6,R 7和R 8独立地选自C 1 -C 8烷基,C 2 -C 8烯基,C 2 -C 8炔基或稳定的单环,双环或三环系; G是-O - , - S - , - CHR 10 - , - C(-O) - ; J是-CH 2 - ,或者当G是CHR 10时也可以是-O-或-NH-; R 10是H,F,-CH 3,-CH 2 NH 2,-CH 2 OH; -OH R 11是H,F,-CH 3,-CH 2 NH 2,-CH 2 OH,-CH(OH)CH 3,CH(NH 3)CH 3; 或R 10和R 11一起界定烯键,或一起形成-CH 2 - 基团,由此限定顺式或反式环丙基; 可用于预防或治疗诸如疟疾的原生动物疾病。

    Dutpase inhibitors
    2.
    发明授权
    Dutpase inhibitors 失效
    Dutpase抑制剂

    公开(公告)号:US08017620B2

    公开(公告)日:2011-09-13

    申请号:US12849765

    申请日:2010-08-03

    IPC分类号: C07D239/54 A61K31/505

    摘要: Deoxyuridine derivatives of the formula where R1 is H or various substituents; D is —NHCO—, —CONH—, —O—, —C(═O)—, —CH═CH, —C≡C—, —NR5—; R4 is hydrogen or various substituents; R5 is H, C1-C4 alkyl, C1-C4 alkanoyl; E is Si or C; R6, R7 and R8 are independently selected from C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl or a stable monocyclic, bicyclic or tricyclic ring system; G is —O—, —S—, —CHR10—, —C(═O)—; J is —CH2—, or when G is CHR10 may also be —O— or —NH—; R10 is H, F, —CH3, —CH2NH2, —CH2OH, —OH; R11 is H, F, —CH3, —CH2NH2, —CH2OH, CH(OH)CH3, CH(NH2)CH3; or R10 and R11 together define an olefinic bond, or together form a —CH2-group, thereby defining a cis or trans cyclopropyl group; have utility in the prophylaxis or treatment of protozoal diseases such as malaria.

    摘要翻译: 其中R 1为H或各种取代基的下式的脱氧尿苷衍生物; D是-NHCO-,-CONH - , - O - , - C(= O) - , - CH = CH,-C≡C-,-NR5-; R4是氢或各种取代基; R5是H,C1-C4烷基,C1-C4烷酰基; E为Si或C; R 6,R 7和R 8独立地选自C 1 -C 8烷基,C 2 -C 8烯基,C 2 -C 8炔基或稳定的单环,双环或三环系; G是-O - , - S - , - CHR 10 - , - C(= O) - ; J是-CH 2 - ,或者当G是CHR 10时也可以是-O-或-NH-; R 10是H,F,-CH 3,-CH 2 NH 2,-CH 2 OH,-OH; R 11是H,F,-CH 3,-CH 2 NH 2,-CH 2 OH,CH(OH)CH 3,CH(NH 2)CH 3; 或R 10和R 11一起界定烯键,或一起形成-CH 2 - 基团,由此限定顺式或反式环丙基; 可用于预防或治疗诸如疟疾的原生动物疾病。

    DUTPASE INHIBITORS
    6.
    发明申请
    DUTPASE INHIBITORS 失效
    DUTPASE抑制剂

    公开(公告)号:US20110021459A1

    公开(公告)日:2011-01-27

    申请号:US12849765

    申请日:2010-08-03

    摘要: Deoxyuridine derivatives of the formula where R1 is H or various substituents; D is —NHCO—, —CONH—, —O—, —C(═O)—, —CH═CH, —C≡C—, —NR5—; R4 is hydrogen or various substituents; R5 is H, C1-C4 alkyl, C1-C4 alkanoyl; E is Si or C; R6, R7 and R8 are independently selected from C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl or a stable monocyclic, bicyclic or tricyclic ring system; G is —O—, —S—, —CHR10—, —C(═O)—; J is —CH2—, or when G is CHR10 may also be —O— or —NH—; R10 is H, F, —CH3, —CH2NH2, —CH2OH, —OH; R11 is H, F, —CH3, —CH2NH2, —CH2OH, CH(OH)CH3, CH(NH2)CH3; or R10 and R11 together define an olefinic bond, or together form a —CH2-group, thereby defining a cis or trans cyclopropyl group; have utility in the prophylaxis or treatment of protozoal diseases such as malaria.

    摘要翻译: 其中R 1为H或各种取代基的下式的脱氧尿苷衍生物; D是-NHCO-,-CONH - , - O - , - C(= O) - , - CH = CH,-C≡C-,-NR5-; R4是氢或各种取代基; R5是H,C1-C4烷基,C1-C4烷酰基; E为Si或C; R 6,R 7和R 8独立地选自C 1 -C 8烷基,C 2 -C 8烯基,C 2 -C 8炔基或稳定的单环,双环或三环系; G是-O - , - S - , - CHR 10 - , - C(= O) - ; J是-CH 2 - ,或者当G是CHR 10时也可以是-O-或-NH-; R 10是H,F,-CH 3,-CH 2 NH 2,-CH 2 OH,-OH; R 11是H,F,-CH 3,-CH 2 NH 2,-CH 2 OH,CH(OH)CH 3,CH(NH 2)CH 3; 或R 10和R 11一起界定烯键,或一起形成-CH 2 - 基团,由此限定顺式或反式环丙基; 可用于预防或治疗诸如疟疾的原生动物疾病。

    DUTPase inhibitors
    7.
    发明授权
    DUTPase inhibitors 失效
    DUTPase抑制剂

    公开(公告)号:US07795270B2

    公开(公告)日:2010-09-14

    申请号:US10585283

    申请日:2005-01-06

    IPC分类号: A61K31/505 C07D239/54

    摘要: Deoxyuridine derivatives of the formula (I) where R1 is H or various substituents; D is —NHCO—, —CONH—, -0-, —C(═O)—, —CH═CH, —C≡C—, —NR5—; R4 is hydrogen or various substituents; R5 is H, C1-C4 alkyl, C1-C4 alkanoyl; E is Si or C; R6, R7 and R8 are independently selected from C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl or a stable monocyclic, bicyclic or tricyclic ring system; G is —O—, —S—, —CHR10—, —C(═O)—; J is —CH2—, or when G is CHR10 may also be —O— or —NH—; R10 is H, F, —CH3, —CH2NH2, —CH2OH; —OHR11 is H, F, —CH3, —CH2NH2, —CH2OH, —CH(OH)CH3, CH(NH3)CH3; or R10 and R11 together define an olefinic bond, or together form a —CH2-group, thereby defining a cis or trans cyclopropyl group; have utility in the prophylaxis or treatment of protozoal diseases such as malaria.

    摘要翻译: 式(I)的脱氧尿苷衍生物,其中R 1为H或各种取代基; D是-NHCO - , - CONH - , - O - , - C(= O) - , - CH = CH,-C≡C-,-NR5-; R4是氢或各种取代基; R5是H,C1-C4烷基,C1-C4烷酰基; E为Si或C; R 6,R 7和R 8独立地选自C 1 -C 8烷基,C 2 -C 8烯基,C 2 -C 8炔基或稳定的单环,双环或三环系; G是-O - , - S - , - CHR 10 - , - C(= O) - ; J是-CH 2 - ,或者当G是CHR 10时也可以是-O-或-NH-; R 10是H,F,-CH 3,-CH 2 NH 2,-CH 2 OH; -OH R 11是H,F,-CH 3,-CH 2 NH 2,-CH 2 OH,-CH(OH)CH 3,CH(NH 3)CH 3; 或R 10和R 11一起界定烯键,或一起形成-CH 2 - 基团,由此限定顺式或反式环丙基; 可用于预防或治疗诸如疟疾的原生动物疾病。